Twin study reveals non-heritable immune perturbations in multiple sclerosis.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
03 2022
Historique:
received: 18 03 2021
accepted: 04 01 2022
pubmed: 18 2 2022
medline: 21 4 2022
entrez: 17 2 2022
Statut: ppublish

Résumé

Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system underpinned by partially understood genetic risk factors and environmental triggers and their undefined interactions

Identifiants

pubmed: 35173329
doi: 10.1038/s41586-022-04419-4
pii: 10.1038/s41586-022-04419-4
pmc: PMC8891021
doi:

Substances chimiques

IL2 protein, human 0
Interleukin-2 0
OX40 Ligand 0
TNFSF4 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Twin Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

152-158

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s).

Références

Wallin, M. T. et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 269–285 (2019).
doi: 10.1016/S1474-4422(18)30443-5
O’Gorman, C., Lin, R., Stankovich, J. & Broadley, S. A. Modelling genetic susceptibility to multiple sclerosis with family data. Neuroepidemiology 40, 1–12 (2012).
pubmed: 23075677 doi: 10.1159/000341902
Sawcer, S. et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214–219 (2011).
pubmed: 21833088 pmcid: 3182531 doi: 10.1038/nature10251
Simpson, S., Blizzard, L., Otahal, P., Van Der Mei, I. & Taylor, B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 82, 1132–1141 (2011).
pubmed: 21478203 doi: 10.1136/jnnp.2011.240432
Nielsen, N. M. et al. Neonatal vitamin D status and risk of multiple sclerosis: a population-based case–control study. Neurology 88, 44–51 (2017).
pubmed: 27903815 pmcid: 5200855 doi: 10.1212/WNL.0000000000003454
Gardener, H. et al. Prenatal and perinatal factors and risk of multiple sclerosis. Epidemiology 20, 611–618 (2009).
pubmed: 19333127 pmcid: 3132937 doi: 10.1097/EDE.0b013e31819ed4b9
Compston, A. & Coles, A. Multiple sclerosis. Lancet 372, 1502–1517 (2008).
pubmed: 18970977 doi: 10.1016/S0140-6736(08)61620-7
Westerlind, H. et al. Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden. Brain 137, 770–778 (2014).
pubmed: 24441172 pmcid: 3927700 doi: 10.1093/brain/awt356
Patsopoulos, N. A. et al. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365, eaav7188 (2019).
doi: 10.1126/science.aav7188
International Multiple Sclerosis Genetics Consortium, Low-frequency and rare-coding variation contributes to multiple sclerosis risk. Cell 175, 1679–1687.e7 (2018).
doi: 10.1016/j.cell.2018.09.049
Hartmann, F. J. et al. Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human T
pubmed: 25278028 doi: 10.1038/ncomms6056
Smets, I. et al. Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. Brain 141, 786–796 (2018).
pubmed: 29361022 pmcid: 5837558 doi: 10.1093/brain/awx372
Jelcic, I. et al. Memory B cells activate brain-homing, autoreactive CD4
pubmed: 30173916 pmcid: 6191934 doi: 10.1016/j.cell.2018.08.011
Galli, E. et al. GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis. Nat. Med. 25, 1290–1300 (2019).
pubmed: 31332391 pmcid: 6689469 doi: 10.1038/s41591-019-0521-4
Tzartos, J. S. et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172, 146–155 (2008).
pubmed: 18156204 pmcid: 2189615 doi: 10.2353/ajpath.2008.070690
Duddy, M. et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178, 6092–6099 (2007).
pubmed: 17475834 doi: 10.4049/jimmunol.178.10.6092
Roederer, M. et al. The genetic architecture of the human immune system: a bioresource for autoimmunity and disease pathogenesis. Cell 161, 387–403 (2015).
pubmed: 25772697 pmcid: 4393780 doi: 10.1016/j.cell.2015.02.046
Brodin, P. et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 160, 37–47 (2015).
pubmed: 25594173 pmcid: 4302727 doi: 10.1016/j.cell.2014.12.020
Vogel, D. Y. S. et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J. Neuroinflammation 10, 35 (2013).
pubmed: 23452918 pmcid: 3610294 doi: 10.1186/1742-2094-10-35
Frischer, J. M. et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132, 1175–1189 (2009).
pubmed: 19339255 pmcid: 2677799 doi: 10.1093/brain/awp070
Mildner, A. et al. CCR2
pubmed: 19531531 doi: 10.1093/brain/awp144
King, I. L., Dickendesher, T. L. & Segal, B. M. Circulating Ly-6C
pubmed: 19196868 pmcid: 2665891 doi: 10.1182/blood-2008-07-168575
Croxford, A. L. et al. The cytokine GM-CSF drives the inflammatory signature of CCR2
pubmed: 26341401 doi: 10.1016/j.immuni.2015.08.010
Dutertre, C. A. et al. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. Immunity 51, 573–589.e8 (2019).
pubmed: 31474513 doi: 10.1016/j.immuni.2019.08.008
Becht, E. et al. InfinityFlow: high-throughput single-cell quantification of 100s of proteins using conventional flow cytometry and machine learning. Preprint at https://doi.org/10.1101/2020.06.17.152926 (2020).
Marrie, R. A. & Rudick, R. A. Drug insight: interferon treatment in multiple sclerosis. Nat. Clin. Pract. Neurol. 2, 34–44 (2006).
pubmed: 16932519 doi: 10.1038/ncpneuro0088
The International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357, 851–862 (2007).
doi: 10.1056/NEJMoa073493
Ahsan, M. K. et al. Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2. Oncogene 25, 2181–2191 (2006).
pubmed: 16314839 doi: 10.1038/sj.onc.1209256
Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180–190 (2012).
pubmed: 22343569 doi: 10.1038/nri3156
Lee, P. W., Xin, M. K., Pei, W., Yang, Y. & Lovett-Racke, A. E. IL-3 is a marker of encephalitogenic T cells, but not essential for CNS autoimmunity. Front. Immunol. 9, 1255 (2018).
pubmed: 29915594 pmcid: 5994593 doi: 10.3389/fimmu.2018.01255
Cao, Y. et al. Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci. Transl. Med. 7, 287ra74 (2015).
pubmed: 25972006 pmcid: 4497538 doi: 10.1126/scitranslmed.aaa8038
Ruan, Q. et al. The Th17 immune response is controlled by the Rel–RORγ–RORγT transcriptional axis. J. Exp. Med. 208, 2321–2333 (2011).
pubmed: 22006976 pmcid: 3201209 doi: 10.1084/jem.20110462
Hussman, J. P. et al. GWAS analysis implicates NF-κB-mediated induction of inflammatory T cells in multiple sclerosis. Genes Immun. 208, 2321–2333 (2016).
Chitnis, T. et al. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J. Clin. Invest. 108, 739–747 (2001).
pubmed: 11544280 pmcid: 209380 doi: 10.1172/JCI200112563
Schneider-Hohendorf, T. et al. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J. Exp. Med. 211, 1833–1846 (2014).
pubmed: 25135296 pmcid: 4144733 doi: 10.1084/jem.20140540
Rudick, R. A. et al. Natalizumab plus Interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354, 911–923 (2006).
pubmed: 16510745 doi: 10.1056/NEJMoa044396
de Craen, A. J. M. et al. Heritability estimates of innate immunity: an extended twin study. Genes Immun. 6, 167–170 (2005).
pubmed: 15674372 doi: 10.1038/sj.gene.6364162
Gerdes, L. A. et al. Immune signatures of prodromal multiple sclerosis in monozygotic twins. Proc. Natl Acad. Sci. USA 117, 21546–21556 (2020).
pubmed: 32817525 pmcid: 7474627 doi: 10.1073/pnas.2003339117
Chuluundorj, D., Harding, S. A., Abernethy, D. & La Flamme, A. C. Expansion and preferential activation of the CD14
pubmed: 24638064 doi: 10.1038/icb.2014.15
Gjelstrup, M. C. et al. Subsets of activated monocytes and markers of inflammation in incipient and progressed multiple sclerosis. Immunol. Cell Biol. 96, 160–174 (2018).
pubmed: 29363161 doi: 10.1111/imcb.1025
Waschbisch, A. et al. Pivotal role for CD16
pubmed: 26746191 doi: 10.4049/jimmunol.1501960
Spath, S. et al. Dysregulation of the cytokine GM-CSF induces spontaneous phagocyte invasion and immunopathology in the central nervous system. Immunity 46, 245–260 (2017).
pubmed: 28228281 doi: 10.1016/j.immuni.2017.01.007
Weber, F. et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun. 9, 259–263 (2008).
pubmed: 18354419 doi: 10.1038/gene.2008.14
Dendrou, C. A. et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat. Genet. 41, 1011–1015 (2009).
pubmed: 19701192 pmcid: 2749506 doi: 10.1038/ng.434
Codarri, L. et al. RORγ3T drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12, 560–567 (2011).
pubmed: 21516112 doi: 10.1038/ni.2027
Noster, R. et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci. Transl. Med. 6, 241ra80 (2014).
pubmed: 24944195 doi: 10.1126/scitranslmed.3008706
Pekalski, M. L. et al. Postthymic expansion in human CD4 naive T cells defined by expression of functional high-affinity IL-2 receptors. J. Immunol. 190, 2554–2566 (2013).
pubmed: 23418630 doi: 10.4049/jimmunol.1202914
Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162–173 (2018).
pubmed: 29275977 doi: 10.1016/S1474-4422(17)30470-2
Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69, 292–302 (2011).
pubmed: 21387374 pmcid: 3084507 doi: 10.1002/ana.22366
Bushnik, T. in Encyclopedia of Clinical Neuropsychology (eds Kreutzer, J. S., DeLuca, J. & Caplan, B.) https://doi.org/10.1007/978-3-319-57111-9_1805 (Springer, 2018).
Hartmann, F. J. et al. High-dimensional single-cell analysis reveals the immune signature of narcolepsy. J. Exp. Med. 213, 2621–2633 (2016).
pubmed: 27821550 pmcid: 5110028 doi: 10.1084/jem.20160897
Finck, R. et al. Normalization of mass cytometry data with bead standards. Cytom. Part A 83, 483–494 (2013).
doi: 10.1002/cyto.a.22271
McInnes, L., Healy, J., Saul, N. & Großberger, L. UMAP: uniform manifold approximation and projection. J. Open Source Softw. 3, 861 (2018).
doi: 10.21105/joss.00861
Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytom. Part A 87, 636–645 (2015).
doi: 10.1002/cyto.a.22625
Ingelfinger, F. et al. Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. Acta Neuropathol. 141, 901–915 (2021).
pubmed: 33774709 pmcid: 8113175 doi: 10.1007/s00401-021-02299-y
Weber, L. M., Nowicka, M., Soneson, C. & Robinson, M. D. diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering. Commun. Biol. 2, 183 (2019).
pubmed: 31098416 pmcid: 6517415 doi: 10.1038/s42003-019-0415-5
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289–300 (1995).
Spitzer, M. H. et al. An interactive reference framework for modeling a dynamic immune system. Science 349, 1259425 (2015).
pubmed: 26160952 pmcid: 4537647 doi: 10.1126/science.1259425
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e29 (2021).
pubmed: 34062119 pmcid: 8238499 doi: 10.1016/j.cell.2021.04.048
Garcia-Alonso, L., Holland, C. H., Ibrahim, M. M., Turei, D. & Saez-Rodriguez, J. Benchmark and integration of resources for the estimation of human transcription factor activities. Genome Res. 29, 1363–1375 (2019).
pubmed: 31340985 pmcid: 6673718 doi: 10.1101/gr.240663.118
Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381–386 (2014).
pubmed: 24658644 pmcid: 4122333 doi: 10.1038/nbt.2859
Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).
pubmed: 29409532 pmcid: 5802054 doi: 10.1186/s13059-017-1382-0
Bates, T. C., Maes, H. & Neale, M. C. Umx: twin and path-based structural equation modeling in R. Twin Res. Hum. Genet. 22, 27–41 (2019).
pubmed: 30944056 doi: 10.1017/thg.2019.2
Verweij, K. J. H., Mosing, M. A., Zietsch, B. P. & Medland, S. E. Estimating heritability from twin studies. Methods Mol. Biol. 850, 151–170 (2012).
pubmed: 22307698 doi: 10.1007/978-1-61779-555-8_9

Auteurs

Florian Ingelfinger (F)

Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Department of Neurology, University Hospital Zurich, Zurich, Switzerland.

Lisa Ann Gerdes (LA)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.
Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.

Vladyslav Kavaka (V)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.

Sinduya Krishnarajah (S)

Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.

Ekaterina Friebel (E)

Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.

Edoardo Galli (E)

Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Neurologic Clinic and Policlinic, University Hospital Basel, Department of Biomedicine, University of Basel, Basel, Switzerland.

Pascale Zwicky (P)

Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.

Reinhard Furrer (R)

Department of Mathematics, University of Zurich, Zurich, Switzerland.
Department of Computational Science, University of Zurich, Zurich, Switzerland.

Christian Peukert (C)

Department of Strategy, Globalization and Society, University of Lausanne, Lausanne, Switzerland.

Charles-Antoine Dutertre (CA)

Gustave Roussy Cancer Campus, Villejuif, France.
Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France.

Klara Magdalena Eglseer (KM)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.

Florent Ginhoux (F)

Singapore Immunology Network, A*STAR, Singapore, Singapore.

Andrea Flierl-Hecht (A)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.
Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.

Tania Kümpfel (T)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.
Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.

Donatella De Feo (D)

Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.

Bettina Schreiner (B)

Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
Department of Neurology, University Hospital Zurich, Zurich, Switzerland.

Sarah Mundt (S)

Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.

Martin Kerschensteiner (M)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.
Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.

Reinhard Hohlfeld (R)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.
Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.

Eduardo Beltrán (E)

Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany.
Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Martinsried, Germany.
Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.

Burkhard Becher (B)

Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. becher@immunology.uzh.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH